Vivoryon Therapeutics is expected to start enrollment for a Phase IIb trial of its lead Alzheimer’s disease treatment in the second quarter of 2020 in Europe, with topline data due in late-2022. Ulrich Dauer, who joined the company as CEO in 2018, spoke to In Vivo during the recent, virtual BIO-Europe Spring conference about the company’s work in Alzheimer’s, how they are approaching the challenges raised by the coronavirus outbreak and their goals for the remainder of 2020.
Vivoryon Brings 'Diversity' To Therapeutic Approach In Alzheimer’s
Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.
More from Innovation
More from In Vivo
• By
In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
• By
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
• By
Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.